MOUNTAINSIDE, NJ - Proteonomix, Inc. (OTCQB: PROT) (Pinksheets:PROT - News) announces that it has licensed from the Cohen-McNiece Foundation (formed by its President, Michael Cohen, and its Chief Scientific Officer and Vice-President, Ian McNiece, PhD) cellular technology for patients who have suffered myocardial infarctions.
The technology involves a method of preparing and using StromaCels for the treatment of cardiac diseases.
A preferred embodiment of the technology is:
- Enriching unique cells from bone marrow samples
- Expanding these cells using a proprietary patent-pending method.
- Harvesting the StromaCel product for potential therapeutic use.
The StromaCel patent application is U.S. Provisional Patent Application Serial No. 61/249,195, filed October 6, 2009.
Ian McNiece, PhD, Chief Scientific Officer, stated: "StromaCel™ is a uniquely isolated, enriched and expanded cellular product derived from bone marrow cells. It has the potential to integrate into damaged heart tissue and promote regeneration of cardiomyocytes, the primary muscle cells of the heart. Regeneration is achieved through the regrowth of cells which make up the microenvironment of heart tissue. This microenvironment supports development of cardiac blood vessels and stem cells to maintain homeostasis. Unlike other cellular products under development derived from the patient's own body, StromaCel™ cells are derived from a non-related donor and have virtually no immune rejection response. We believe that StromaCel™ cells may one day be used for the repair of damaged heart tissue without the need to store cells for the donor's future use."
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm, has developed a line of anti-aging cosmetics. Please visit www.proteonomix.com, www.proteoderm.com, www.otcqb.com and www.sec.gov.
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release relating to the development and potential therapeutic use of StromaCels constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.